Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment

Title
Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment
Authors
Keywords
Atherosclerosis, Sirolimus, Paclitaxel, Hypoxia, HIF-1α, Glycolysis
Journal
Bioactive Materials
Volume 6, Issue 3, Pages 880-889
Publisher
Elsevier BV
Online
2020-10-01
DOI
10.1016/j.bioactmat.2020.09.005

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now